|
|
Eterna Therapeutics Inc (NASDAQ: ERNA) |
|
Price: $0.2740
$0.02 
6.656%
|
| Day's High:
| $0.275
| Week Perf:
| 2.2 %
|
| Day's Low: |
$ 0.26 |
30 Day Perf: |
-4.79 % |
| Volume (M): |
84 |
52 Wk High: |
$ 2.63 |
| Volume (M$): |
$ 23 |
52 Wk Avg: |
$1.28 |
| Open: |
$0.26 |
52 Wk Low: |
$0.22 |
|
|
| Market Capitalization (Millions $) |
1 |
| Shares
Outstanding (Millions) |
5 |
| Employees |
36 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-45 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
0 |
Eterna Therapeutics Inc
Eterna Therapeutics Inc, also known as Eterna, is a biotechnology company that is focused on the development of mRNA-based therapies. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Eterna is driven by a mission to advance the field of RNA therapeutics, with a focus on leveraging the power of messenger RNA (mRNA) to develop precise and effective treatments for a range of diseases. The company's proprietary mRNA platform is designed to enable the rapid development of targeted, safe, and potent therapies, using a modular approach that can be easily adapted to specific therapeutic targets.
Eterna's approach to mRNA therapy is distinguished by its use of "pure" mRNA, which is unmodified and free from any chemical modifications that could potentially limit its therapeutic potential. This approach allows for the creation of highly precise mRNA sequences that can be tailored to the specific needs of each patient.
Eterna has a number of ongoing research programs in a range of therapeutic areas, including oncology, immunology, and rare genetic disorders. Its lead product candidate is currently in preclinical development, aimed at the treatment of solid tumors.
The company has built a strong team of experts in RNA biology, drug development, and clinical research, and has collaborated with a number of leading academic and research institutions to advance its pipeline of mRNA therapies.
Eterna is supported by a group of prominent investors, including Fidelity, Omega Funds, and Cormorant Asset Management, among others. The company has raised approximately $70 million in total funding to date.
Company Address: 1035 Cambridge Street, Suite 18A Cambridge 2141 MA
Company Phone Number: 582-1199 Stock Exchange / Ticker: NASDAQ ERNA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Management Changes
Published Thu, Jan 9 2025 12:30 PM UTC
CAMBRIDGE, Mass.?In a bold move, Eterna Therapeutics Inc. recently announced the appointment of Dr. Elena Ratner, a world-renowned expert in obstetrics and gynecology from Yale University, to its Board of Directors. The company is aiming to leverage Dr. Ratner s extensive experience to enhance its ongoing research in ovarian cancer, a critical area of focus for the biotech f...
|
| Eterna Therapeutics Inc
Eterna Therapeutics Inc, a leading life science company focused on harnessing the potential of mRNA cell engineering, has experienced significant fluctuations in its stock price over the past few months. Despite a recent gain of 14.78% over the last five trading days, the stock is still down by 12.17% for the second quarter of 2024. Currently trading on the NASDAQ slightly above its 52-week average, the company is showing signs of resilience in the face of market volatility.
One of the key factors influencing Eterna Therapeutics Inc's stock performance is its financial results. In the most recent fiscal period, the company reported revenue of $0.047 million, indicating modest earnings growth. However, it also posted a net loss of $-6.647 million, which is higher than the $-5.416 million loss from the previous year. Despite these losses, the company remains focused on advancing its mRNA cell engineering capabilities to develop revolutionary new medications.
|
| Eterna Therapeutics Inc
In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.
|
| Financing Agreement
Published Thu, Dec 14 2023 11:56 PM UTC
Eterna Therapeutics: Secures $9.2 Million Funding for Advancing mRNA Cell Engineering
CAMBRIDGE, Mass., Dec. 14, 2023 - Eterna Therapeutics Inc. (Nasdaq: ERNA), a leading life science company focused on harnessing the potential of mRNA cell engineering to develop revolutionary new medications, recently disclosed the execution of a securities purchase agreement with accre...
|
| Eterna Therapeutics Inc
In the midst of a challenging economic landscape, the stock market has been steadily showing signs of recovery. Eterna Therapeutics Inc, a major pharmaceutical preparations company, has emerged as an exciting player in this space. With a recent disclosure of $0.051 million in revenues, a significant reduction in net shortfall, and an increase in accounts receivable, Eterna Therapeutics Inc is poised for success. In this article, we will delve deeper into these positive indications and explore the potential prospects for investors in this company.
Increased Revenue and Improved Financial Outlook:
Eterna Therapeutics Inc has made substantial progress by reporting a revenue of $0.051 million in the most recent fiscal period. This growth is not just limited to revenues; the company has also shown a remarkable reduction in its net shortfall. From a deficit of $-7.316 million in the previous year's reporting season, the net shortfall has now considerably decreased to $-5.591 million. This dynamic shift is a clear indication of the company's improved financial performance and management's ability to navigate challenging market conditions effectively.
|
| Per Share |
Current |
| Earnings (TTM) |
-7.95 $ |
| Revenues (TTM) |
0.11 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.79 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-7.95 $
|
| Revenues (TTM) |
0.11 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.79 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.1% 